- Practical aspects of metastatic castration-resistant prostate cancer management: patient case studiesAmit Bahl
Bristol Haematology and Oncology Centre, University Hospitals Bristol, UK
BJU Int 109:14-9. 2012..The development of second-line chemotherapeutic agents together with the use of prognostic factors and a patient-centred multidisciplinary team approach provide encouraging new management prospects for patients with mCRPC...
- Metastatic castrate-resistant prostate cancer: dawn of a new age of managementSusan Masson
Bristol Haematology and Oncology Centre, Bristol, UK
BJU Int 110:1110-4. 2012..Further studies and ongoing clinical experience are likely to clarify this important issue, and help clinicians to maximise the survival of men with mCRPC post-docetaxel...
- Do we need to obtain consent for penile shortening as a complication of treatment for organ-confined prostate cancer?Maike F Eylert
Department of Urology, Bristol Royal Infirmary, UK
BJU Int 110:1491-500. 2012..To establish an evidence base to guide consenting for treatment of organ-confined prostate cancer with regard to penile shortening...